Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer

Am J Clin Oncol. 2001 Aug;24(4):421-4. doi: 10.1097/00000421-200108000-00026.


We report a case in which brain metastases originating from breast cancer responded to treatment with oral capecitabine. The metastases had progressed and Karnofsky performance status deteriorated despite whole brain irradiation, hormonal treatment, and systemic chemotherapy that included 5-fluorouracil (5-FU). In contrast, 2 months of treatment with oral capecitabine produced a partial response, documented by lesion size on magnetic resonance imaging and an improvement in performance status; both measures continued to improve during 11 months of capecitabine treatment.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antimetabolites, Antineoplastic / therapeutic use*
  • Brain Neoplasms / diagnosis
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / secondary*
  • Breast Neoplasms / pathology*
  • Capecitabine
  • Deoxycytidine / analogs & derivatives
  • Deoxycytidine / therapeutic use*
  • Drug Resistance, Neoplasm
  • Female
  • Fluorouracil / therapeutic use
  • Humans
  • Magnetic Resonance Imaging
  • Prodrugs / therapeutic use*


  • Antimetabolites, Antineoplastic
  • Prodrugs
  • Deoxycytidine
  • Capecitabine
  • Fluorouracil